Articles tagged "Heart"

2020 American Transplant Congress
Inducing Donor MHC Chimerism with Bone Marrow Derived Exosomes in Non-Human Primates
P. M. Patel¹, B. A. Gonzalez Nolasco¹, J. A. Morrissette¹, A. Prunevieille¹, K. J. Ahrens¹, J. M. O¹, D. C. Becerra¹, G. Benichou¹, J. C. Madsen²
¹Surgery, Center for Transplantation Sciences, Massachusetts General Hospital/Harvard Medical School, Boston, MA, ²Surgery, Center for Transplantation Sciences, Division of Cardiac Surgery, Massachusetts General Hospital/Harvard Medical School, Boston, MA
*Purpose: Cardiac allograft tolerance in non-human primates (NHPs) has been achieved by our group via hematopoietic mixed chimerism consisting of an allogeneic bone marrow (BM)…
2020 American Transplant Congress
Variations in Recipient and Donor Clinical Characteristics between Heart Transplant Centers
W. T. McKinney¹, M. J. Bruin², S. Chu², D. Schladt³, J. Synder³, C. M. Martin⁴, T. Alexy⁴, B. L. Kasiske⁵, A. K. Israni¹
¹Nephrology, Hennepin Healthcare Research Institute, Minneapolis, MN, ²College of Design, University of Minnesota, Minneapolis, MN, ³Hennepin Healthcare Research Institute, Minneapolis, MN, ⁴Cardiology Division, University of Minnesota Department of Medicine, Minneapolis, MN, ⁵Department of Medicine, Hennepin Healthcare, Minneapolis, MN
*Purpose: When a patient has discretion over which heart transplant program will evaluate them for the waitlist, prior knowledge of program acceptance practices can enable…
2020 American Transplant Congress
The Effect of UNOS Donor Policy Change on Ischemic Time and the Effects on Mortality in Heart Transplantation
A. Lee¹, K. Yang¹, G. Liu¹, C. Lum², A. D. Salimbangon³, R. R. Chand⁴, P. Banankhah¹, P. Genyk¹, P. Kingsford¹, J. Li¹, J. Li¹, D. Vucicevic⁵, K. Pandya¹, J. Rahman¹, M. Fong¹, L. Grazette¹, A. Kiankhooy¹, J. [email protected]¹, S. Hashmi¹, A. Gong¹, J. Pizula¹, D. Miklin¹, S. Shah¹, A. Vaidya¹, A. Wolfson⁶, E. Depasquale¹
¹Keck Medicine of USC, Los Angeles, CA, ²The Queens Medical Center, Honolulu, HI, ³UCLA Medical Center, Los Angeles, CA, ⁴Harbor-UCLA Medical Center, Los Angeles, CA, ⁵Newark Beth-Israel Medical Center, Newark, NJ, ⁶University of Arizona Sarver Heart Center, Tuscon, AZ
*Purpose: In light of the recent change in the UNOS allocation policy, we sought to evaluate the impact of ischemic time on mortality.*Methods: Using the…
2019 American Transplant Congress
Prevalence of Donor Specific Antibody in Heart Transplant Recipients with Antibody-Mediated Rejection as Compared to Abnormal Intragraft mRNA Transcripts by Molecular Microscope System
K. Shah, R. J. Levine, S. Dimbil, S. Sana, P. F. Halloran, J. Patel, D. H. Chang, E. Kransdorf, M. Kittleson, J. A. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: Antibody-mediated rejection (AMR) is defined by pathologic evaluation of endomyocardial biopsy (EMB) for both histologic and immunopathologic components. Detectable donor specific antibodies (DSAs) in…
2019 American Transplant Congress
Tolerance to ABO A-Antigen Following Treatment of Infant Mice with A-Expressing MHC-Identical Erythrocytes
B. Motyka¹, J. Fersovich¹, M. Sulzer¹, I. Adam¹, J. Pearcey¹, K. Tao¹, C. W. Cairo², P. J. Cowan³, L. J. West¹
¹Dept Pediatrics, Alberta Transplant Institute, Canadian Donation and Transplant Research Program, University of Alberta, Edmonton, AB, Canada, ²Department of Chemistry, University of Alberta, Edmonton, AB, Canada, ³Immunology Research Centre, St Vincent's Hospital, Melbourne, Australia
*Purpose: ABO-incompatible heart transplantation (ABOi HTx) is safe in young children and increases donor access. Post-ABOi HTx, B cell tolerance develops to donor ABO blood…
2019 American Transplant Congress
Unfair Waiting Time Calculation? Impact of Accumulated Wait Time Restart with a Decrease in Status from 1A to 1B or 2 on Mortality of Heart Transplant Candidates
S. Yu, M. Kosztowski, M. Waldram, D. L. Segev, A. B. Massie
Department of Surgery, Johns Hopkins, Baltimore, MD
*Purpose: Between two heart transplant (HT) candidates listed at the same status, the candidate with longer accumulated wait time receives higher waitlist priority; under current…
2019 American Transplant Congress
ECDI-Treated Donor Leukocytes in Primate Cardiac Allograft Recipients
Z. Alikhassy Habibabady¹, T. Zhang², W. Sun², X. Cheng², L. Burdorf¹, I. Tatarov², S. Sendil², I. Behroozfard², B. Cerel¹, D. Parsell², R. N. Pierson III¹, X. Luo³, A. M. Azimzadeh¹
¹Surgery, Massachusetts General Hospital and Harvard School of Medicine, Boston, MA, ²Surgery, University of Maryland School of Medicine, Baltimore, MD, ³Duke Transplant Center, Duke University, Durham, NC
*Purpose: Ethyl carbodiimide (ECDI)-fixed donor leukocytes exhibit tolerogenic immunomodulation in murine models of autoimmunity and transplantation, and nonhuman primate islet transplantation. Here in pilot studies…
2019 American Transplant Congress
A Molecular Analysis of Graft Survival in the INTERHEART Study
P. Halloran¹, J. Reeve and the INTERHEART investigators²
¹University of Alberta, Edmonton AB, AB, Canada, ²ATAGC, University of Alberta, Edmonton AB, AB, Canada
*Purpose: Rejection is a major cause of graft loss in heart and kidney transplants. The principal diagnosis associated with risk in kidneys is antibody-mediated rejection…
2019 American Transplant Congress
Anemia and Hemolysis on Dapsone Despite Normal Glucose-6-Phosphate Dehydrogenase Activity in Heart Transplant Recipients
K. Lor, E. Kransdorf, J. Patel, M. Kittleson, D. Chang, J. A. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: Dapsone has been considered an acceptable alternative for pneumocystis jirovecii pneumonia (PCP) prophylaxis in sulfa-allergic or -intolerant transplant patients with normal glucose-6-phosphate dehydrogenase (G6PD)…
2019 American Transplant Congress
TMA Development in Kidney and Heart Xenografts Treated with Anti-CD40 or Anti-CD154 Antibodies
D. H. Ma¹, H. Sasaki¹, J. M. O¹, K. Ahrens¹, D. Becerra¹, C. G. Rickert¹, D. M. Detelich¹, T. Oura¹, W. Somer¹, I. Rosales², R. N. Pierson¹, J. Markmann¹, J. C. Madsen¹, T. Kawai¹
¹Surgery, MGH, Boston, MA, ²Pathology, MGH, Boston, MA
*Purpose: Genetically modified Galactose-α 1,3-galactose knockout transgenic swine expressing human CD55 (GTKO.hCD55) are resistant to hyperacute rejection of xenografts. We compare anti-CD154 and anti-CD40 antibody-based…

« Previous Page
1
…
8
9
10
11
12
…
22
Next Page »